Patent 6,235,756 protects and is included in zero NDA.
|Title:||Methods and compositions for inhibition of angiogenesis by thalidomide|
|Abstract:||The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.|
|Inventor(s):||D'Amato; Robert (Lancaster, PA)|
|Assignee:||The Children's Medical Center Corporation (Boston, MA)|
Patent Claim Types:|
see list of patent claims
|Use; Dosage form; Formulation;|
|Country||Document Number||Publication Date|
|World Intellectual Property Organization (WIPO)||9420085||Sep 15, 1994|
|United States of America||2003181428||Sep 25, 2003|
|United States of America||2003187024||Oct 02, 2003|
|United States of America||2012142734||Jun 07, 2012|
|United States of America||RE40360||Jun 03, 2008|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.